A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM)
← catalyst calendarNCT06081894 · readout ≤ 12 d
Sponsored by Cytokinetics (industry) · CYTK — their whole pipeline →. With Sanofi, Bayer.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
500estimated
Sites
180
Countries
Argentina, Australia, Brazil +17
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-31 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
Interventions
- Drug: Aficamten
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFChange in Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS)
measured Baseline to Week 36
Change in pVO2
measured Baseline to Week 36
Permalink · CYTK's whole pipeline · Catalyst calendar · Every registered study · What changed